GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Cash-to-Debt

MetaStat (MetaStat) Cash-to-Debt : 0.32 (As of Feb. 2018)


View and export this data going back to 2008. Start your Free Trial

What is MetaStat Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MetaStat's cash to debt ratio for the quarter that ended in Feb. 2018 was 0.32.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, MetaStat couldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2018.

The historical rank and industry rank for MetaStat's Cash-to-Debt or its related term are showing as below:

MTST's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 6.39
* Ranked among companies with meaningful Cash-to-Debt only.

MetaStat Cash-to-Debt Historical Data

The historical data trend for MetaStat's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MetaStat Cash-to-Debt Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.96 0.24 0.79 0.32

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.15 1.74 0.78 0.32

Competitive Comparison of MetaStat's Cash-to-Debt

For the Biotechnology subindustry, MetaStat's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where MetaStat's Cash-to-Debt falls into.



MetaStat Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

MetaStat's Cash to Debt Ratio for the fiscal year that ended in Feb. 2018 is calculated as:

MetaStat's Cash to Debt Ratio for the quarter that ended in Feb. 2018 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MetaStat  (OTCPK:MTST) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


MetaStat Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of MetaStat's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


MetaStat (MetaStat) Business Description

Traded in Other Exchanges
N/A
Address
27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Executives
Daniel H Schneiderman officer: VP OF FINANCE AND SECRETARY 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings director 11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll director C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor director 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel director T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau director 2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein director OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins 10 percent owner 730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz director 10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines